Loading…
To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2022 · fourth_quarter · Health Issues
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; HR 2617 Consolidated Appropriations Act of 2023; Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease; Improving access for patients with orphan diseases; Improved use of FDA rare disease flexibilities
Client expense: Not reported · Firm income: $40,000
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; S 4348 the Food & Drug Administration Safety and Landmark Advancements of 2022; HR 7667 the Food & Drug Administration Amendments of 2022; Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; S 4348 the Food & Drug Administration Safety and Landmark Advancements of 2022; HR 7667 the Food & Drug Administration Amendments of 2022; Ensuring access to treatments for rare disease; Value of rare disease research and development
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE